Metrochem API Private Limited Metrochem API Private Limited

X

Find the latest Drugs in Development and Pipeline Prospector News of GSK.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
GSK
unitedkingdom_new Flag
Country
Country
United Kingdom
Address
Address
980 Great West Road, Brentford, Middlesex TW8 9GS England
Telephone
Telephone
+44 (0)20 8047 5000
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

  • Deals

Details:

The proceeds will enable the clinical development of BioVersys’ portfolio which includes BV100 (rifabutin), a potential breakthrough hospital antibiotic with a new mode of action targeting Acinetobacter baumannii, the most drug-resistant bacterial pathogen.


Lead Product(s): Rifabutin

Therapeutic Area: Infections and Infectious Diseases Product Name: BV100

Highest Development Status: Phase IProduct Type: Small molecule

Recipient: BioVersys AG

Deal Size: $49.5 million Upfront Cash: Undisclosed

Deal Type: Series C Financing May 07, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
  • Deals

Details:

The collaboration with the GSK to accelerate the clinical development of BVL-GSK098 (alpibectir) for the treatment of tuberculosis.


Lead Product(s): Alpibectir,Ethionamide

Therapeutic Area: Infections and Infectious Diseases Product Name: BVL-GSK098

Highest Development Status: Phase IIProduct Type: Small molecule

Recipient: BioVersys AG

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration May 07, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

UK MHRA approved two new formulations of the medicine cabotegravir (Apretude 30 mg film-coated tablets and Apretude 600 mg prolonged-release suspension for injection) to help prevent sexually transmitted HIV-1 infection in adults and adolescents.


Lead Product(s): Cabotegravir

Therapeutic Area: Infections and Infectious Diseases Product Name: Apretude

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 04, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
  • Development Update

Details:

Jemperli (dostarlimab) in combination with Zejula (niraparib) is being evaluated in phase 3 ciical trials for the treatment of primary advanced or recurrent endometrial cancer.


Lead Product(s): Dostarlimab,Niraparib Tosylate

Therapeutic Area: Oncology Product Name: Jemperli

Highest Development Status: Phase IIIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 24, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
  • Deals

Details:

Under the collaboration, GSK has selected its first two programs to advance to development candidates following achievement of target validation. These programs utilize Wave’s next generation GalNAc-siRNA format and are in hepatology.


Lead Product(s): Undisclosed

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

Highest Development Status: PreclinicalProduct Type: Large molecule

Recipient: Wave Life Sciences

Deal Size: $3,312.0 million Upfront Cash: $12.0 million

Deal Type: Collaboration April 23, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
  • Development Update

Details:

GSK 2140944 (gepotidacin) is a potential first-in-class oral antibiotic which inhibits bacterial DNA replication, with a novel mechanism of action for uncomplicated urogenital gonorrhoea (GC) in adolescents and adults.


Lead Product(s): Gepotidacin

Therapeutic Area: Infections and Infectious Diseases Product Name: GSK 2140944

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 17, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
  • Development Update

Details:

US FDA has accepted for review a Biologics License Application for its 5-in-1 meningococcal ABCWY (MenABCWY) vaccine candidate. PDUFA action date for a regulatory decision by the US FDA on this application is 14 February 2025.


Lead Product(s): MenABCWY

Therapeutic Area: Infections and Infectious Diseases Product Name: MenABCWY

Highest Development Status: Phase IIIProduct Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 16, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Dovato (dolutegravir), that combines the integrase strand transfer inhibitor, dolutegravir with the nucleoside reverse transcriptase inhibitor, lamivudine, is the first and only oral, two-drug, single-tablet regimen available for people aged 12 and older living with HIV.


Lead Product(s): Dolutegravir Sodium,Lamivudine

Therapeutic Area: Infections and Infectious Diseases Product Name: Dovato

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 08, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
  • Development Update

Details:

Flu mRNA (GSK4382276A) is a intramuscularly administered mRNA-based multivalent seasonal influenza vaccine, which is being evaluated for the treatment of seasonal influenza.


Lead Product(s): GSK4382276A

Therapeutic Area: Infections and Infectious Diseases Product Name: Flu mRNA

Highest Development Status: Phase IIProduct Type: Vaccine

Recipient: CureVac

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 04, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
  • Development Update

Details:

Jemperli (dostarlimab) in combination with Zejula (niraparib) is being evaluated in phase 3 ciical trials for the treatment of primary advanced or recurrent endometrial cancer.


Lead Product(s): Dostarlimab,Niraparib Tosylate

Therapeutic Area: Oncology Product Name: Jemperli

Highest Development Status: Phase IIIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 16, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY